Encysive Pharmaceuticals (ENCY) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Encysive Pharmaceuticals (ENCY)

An SI Board Since November 2005

Posts	SubjectMarks	Bans
205	11	0

Emcee: tuck	Type: Unmoderated

Introduction Compact

Encysive's Thelin (Sitaxsentan) appears to be nearing commercialization for pulmonary arterial hypertension. It may be the best drug for it when it hits the market.

ENCY already has GSK marketing Argatroban for heparin-induced thrombocytopenia, though I do not now how much that is contributing as I write this.

Further, it has a majority owned subsidiary, Revotar Biopharmaceuticals AG, which is in Phase II development with the selectin antagonist bimosiamose in asthma, psoriasis and atopic dermatitis. I know nothing about this compound at the moment, either.

In summary, ENCY has a quality lead compound, and a pipe with some depth and near term visibility, as well as a marketed product. As such, it strikes me as a company worthy of further investigation. I invite folks to post here on ENCY and its programs, as well as competitors.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
205	If ency/Given had started this trial when the fda first requested, would they be	rkrw	-	9/24/2007
204	European article on approved PAH therapies . . . with a big ad from ENCY	tuck	-	9/5/2007
203	Die hard ENCY: <b>Encysive set for second Thelin trial</b> Tuesday	idos	-	9/4/2007
202	I suppose you noticed that indeed, they are exploring "strategic alternativ	tuck	-	7/22/2007
201	The article doesn't really explain just how it botched, just that it botched	tom pope	-	7/3/2007
200	"How Encysive Botched the FDA Game" thestreet.com It's still a b	tuck	-	7/3/2007
199	It never occurred to me that ENCY would sell for 1.73. What a mess! ij	IRWIN JAMES FRANKEL	-	6/26/2007
198	One very slight silver lining was the black box label for Lentairis (Ambrisentan	tuck	-	6/26/2007
197	Good for shareholders. Turned out Given was not Bruce Almighty.	kenhott	-	6/26/2007
196	Wrong company - brain fog from too much travel. Jon	Robohogs	-	6/26/2007
195	David who? Is that Bruce's middle name? Cheers, Tuck	tuck	-	6/25/2007
194	LOL Jon	Robohogs	-	6/25/2007
193	Good idea, they could rename themselves Offencysive.	rkrw	-	6/25/2007
192	Maybe they should merge with someone like OSCI - have three not big selling drug	Robohogs	-	6/25/2007
191	How much will David get of the $15 MM? Jon	Robohogs	-	6/25/2007
190	>>Encysive Pharmaceuticals Appoints New Chief Executive and Announces Rest	tuck	-	6/25/2007
189	Vague commentary by a blogger who has regulatory background, with comments from	tuck	-	6/25/2007
188	So, according to Given on the CC, it is basically an issue of the FDA violating	tuck	-	6/22/2007
187	Well, Given was right, the FDA's issue was not what everybody thought: it	tuck	-	6/20/2007
186	Right - Tuck. Just thought it worth posting since it is hitting the wires on br	IRWIN JAMES FRANKEL	-	6/11/2007
185	The CEO strongly hinted that the coumadin interaction was not the issue. "	tuck	-	6/11/2007
184	ENCY Encysive Pharma: Dawson James cautiously optimistic for Friday PDUFA date	IRWIN JAMES FRANKEL	-	6/11/2007
183	Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Art	LJM	-	5/30/2007
182	>>Encysive Pharmaceuticals Announces Patient Enrollment Initiated for TBC3	tuck	-	3/21/2007
181	>>Encysive Pharmaceuticals Reports Fourth Quarter and Year End 2006 Financ	tuck	-	3/9/2007

Go to reply# or date (mm/dd/yy):